Overview

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and tolerability of these compounds over the 48 week study period in patients naive to anti-HIV therapy.
Phase:
Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Abacavir
Dideoxynucleosides
Fosamprenavir
Lamivudine
Lopinavir
Ritonavir
Criteria
Inclusion Criteria:

- HIV infected subjects that are naive to anti-HIV therapy.

- History of a positive HIV test.

- At least 1000 copies/mL of HIV in their blood as screening.

Exclusion Criteria:

- Active HIV-related diseases.

- Taking other investigational drugs.

- Pregnant or breastfeeding females.

- Not be suitable to participate per investigator opinion.